Navigation Links
Loss of MicroRNA decoy might contribute to development of soft-tissue sarcoma
Date:8/7/2013

COLUMBUS, Ohio Researchers have discovered a novel mechanism responsible for the loss of a critical tumor-suppressor gene in rhabdomyosarcoma and other soft-tissue sarcomas, rare cancers that strike mainly children and often respond poorly to treatment. Their cause is largely unknown.

Knowledge of the mechanism could guide the development of more effective therapies for these malignancies, say researchers who led the study at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).

The researchers found that the tumor-suppressor gene called A20 is silenced not by mutation, as in many other cancers, but because a second molecule is lost, a small molecule called microRNA-29 (miR-29). In addition, they found that miR-29 normally protects A20 from destruction. When miR-29 is absent, A20 is degraded. Loss of A20, in turn, leads to a dramatic rise in levels of a protein called NF-kB and to tumor progression.

The findings are published in the journal Science Signaling.

"We do know that NF-kB is a tumor promoter, but we don't know why it is upregulated in many cancers," says principal investigator Denis Guttridge, PhD, professor of molecular virology, immunology and medical genetics and a member of the OSUCCC James Molecular Biology and Cancer Genetics Program.

"Our study indicates that it involves a regulatory circuit between NF-kB, miR-29 and the A20 tumor-suppressor gene," Guttridge says. "It also identifies NF-kB as a therapeutic target in sarcoma and A20 and miR-29 as potential biomarkers for sarcoma."

"We are excited about these findings because they open up new vistas on the role of microRNAs in sarcoma development and provide a rationale for further interrogating this circuitry as a potential target for new treatments," says study pathologist and coauthor O. Hans Iwenofu, MD, FCAP, assistant professor of pathology and member of the OSUCCC James Molecular Biology and Cancer Genetics Program.

Soft-tissue sarcomas cancers of muscle, other soft tissues and bone make up about 15 percent of pediatric cancer cases. In 2013, about 11,400 cases of sarcoma are expected in the United States, and about 4,400 Americans are expected to die from the malignancy.

For this study, Guttridge, Iwenofu and their colleagues used human tumor samples, cell lines and animal models. Key technical findings include:

  • miR-29 and A20 expression are abnormally low in sarcomas;
  • The A20 gene showed little evidence of mutation;
  • Restoring miR-29 levels in sarcoma cells caused A20 levels to rise;
  • miR-29 normally binds with a protein called HuR; when miR-29 is absent, HuR binds with A20, leading to the degradation of A20;
  • When miR-29 binds with HuR, it acts as a decoy and protects A20 from HuR-mediated degradation.

"The loss of the A20 tumor-suppressor gene because the microRNA decoy is absent may represent another mechanism to explain why NF-kB is constitutively active in sarcoma cancers," Guttridge says.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center
Source:Eurekalert

Related medicine news :

1. New papers identify a microRNA that drives both cancer onset and metastasis
2. Moffitt Cancer Center researchers say 1 specific microrna promotes tumor growth and cancer spread
3. Atherosclerosis: Specific microRNAs promote inflammation
4. MicroRNA molecule may serve as biomarker, target for brain metastases in breast cancer patients
5. Hepatitis B virus promotes oncogenesis through microRNA modulation
6. MicroRNAs can convert normal cells into cancer promoters
7. Pint-size microRNAs show promise against weighty problem, researchers say
8. A microRNA prognostic marker identified in acute leukemia
9. Extended primary care office hours might help keep kids out of the emergency department
10. Moderate-intensity walking timed just right might help protect against Type 2 diabetes
11. Gene-Based Blood Test Might Help Spot Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Flottman ... and outserts. As a means of expanding capabilities Flottman has added a ... to individually code professional inserts (PIs) and patient package inserts (PPIs) that will ...
(Date:12/9/2016)... , ... December 09, 2016 , ... An inventor from ... to safely ride all types of amusement park rides. , The patent-pending SAFETY STRAP ... is easy to use and could be set up in a matter of minutes, ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying ... Va. "I thought that if the nebulizer had a more child-friendly design, then children ... , He developed the patent-pending NEBY to avoid the need to deliver medication via ...
(Date:12/8/2016)... MA (PRWEB) , ... December 08, 2016 , ... ... Workers Compensation Research Institute (WCRI) officially opened registration today for its 33rd ... Hotel in Boston, MA . , The theme of the conference is “Persistent ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... offering Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has ... general counsel and Eric Hoessel to vice president of sales. , Litsinger ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec 9, 2016 Research ... Screening Market - Forecast to 2021" report to their ... ... of open innovative models in the pharmaceutical and biotechnology industry ... and rising government funding. Emerging markets and growing research activities ...
(Date:12/9/2016)...  RxWiki Inc., a digital health company that powers ... thousands of pharmacies through its Digital Pharmacist SaaS platform, ... "50 on Fire" Award in the Health and Life ... the award as one of Austin,s fastest growing companies," ... RxWiki. "Our platform gives independent retail pharmacies the digital ...
(Date:12/9/2016)... , Dec. 9, 2016  Forge Therapeutics, ... AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) ... ,LpxC, for the treatment of bacterial infections including ... been recognized as an attractive antibacterial target for ... lack of suitable chemical starting points has hampered ...
Breaking Medicine Technology: